N-myc amplification and its relationship to experimental therapy

Journal of Neuro-Oncology

Volumn 31, Issue 1-2, 1997, Pages 33-39

  Livingstone, Anne ^a   Mairs, Robert J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Apoptosis; Cisplatin; N myc; Neuroblastoma; Radiation; VP 16

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DNA; ETOPOSIDE;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA REPAIR; DRUG SENSITIVITY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; ONCOGENE C MYB; PROGNOSIS; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE AMPLIFICATION; GENE THERAPY; GENES, MYC; HUMANS; NEUROBLASTOMA; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0031040026     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005773011779     Document Type: Article

References (35)

1. Livingstone A, Mairs RJ, Russell J, O'Donoghue J, Gaze MN, Wheldon, TE: N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment. Eur J Cancer 30A: 382-389, 1994
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced stage disease. Science 244: 1121-1124, 1984
3. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D: Association of multiple copies of N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116, 1985
4. Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Kimura I: Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line. Acta Med Okayama 46: 203-212, 1992
5. Arnold A, Whitehouse J: Ineraction of VP-16 23 with the DNA repair antagonist chloroquine. Cancer Chemother Pharmacol 7: 123-126, 1982
6. Morrow CS, Cowan KH: Multidrug resistance associated with altered topoisomerase II activity - topoisomerase II as targets for rational drug design. J Natl Cancer Inst 82: 638-639, 1990
7. Canon JL, Humblet Y, Symann M: Resistance to cisplatin: how to deal with the problem? Eur J Cancer 26: 1-3, 1990
8. Sekiya S, Oosaki T, Andoh S, Suzuki N, Akaboshi M, Takamizawa H: Mechanisms of resisitance to cis-diamminedichloroplatinum(II) in a rat ovarian carcinoma line. Eur J Cancer Clin Oncol 25: 429-437, 1989
9. Ireland CM, Pittman SM, Jones SL, Harnett, PR: Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines. Anticancer Res 14: 2397-2404, 1994
10. Van Mannen JM, Retel J, de Vries J, Pinedo HM: Mechanism of action of antitumour drug etoposide: a review. J Natl Cancer Inst 80: 1526-1533, 1988
11. Tumilowicz JJ, Nichols WW, Cholon JJ, Greene AE: Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 30: 2110-2118, 1970
12. Schlesinger HR, Gerson JM, Mooread PS, Maguire H, Hummeler K: Establishment and characterisation of human cell lines. Cancer Res 36: 3094-3100, 1976
13. Biedler JL, Helson L, Spengler BA: Morphology and growth, tumourgenicity and cytogenetics of human neuroblastoma cells on continuous culture. Cancer Res 33: 2643-2652, 1973
14. Reynolds CP, Biedler JL, Spengler BA: Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 76: 375-387, 1986
15. Russell J, Wheldon TE, Stanton P: A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation induced apoptosis. Cancer Res (in press)
16. Schwab M, Alitilo K, Klempnauler KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J: Amplified DNA with limited homolgy to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245-248, 1983.
17. Bartram CR, De Klein A, Hagemeijer A, Carbonell F, Kleihauer E, Grosveld G: Additional C-abl/bcr rearrangements in a CML patient exhibiting two Ph 1 chromosomes during blast crisis. Leukaemia Res 10: 221-225, 1986
18. Davis LG, Dibner MD, Battey JF: Basic Methods in Molecular Biology. Elsevier, New York, 1986, pp 139-149
19. Kohl NE, Gee CE, Alt FW: Activated expression of the N-myc gene in human neuroblastomas and related tumours. Science 266: 1335-1337, 1984
20. Raaphorst GP, Wang G, Wilkins D, Davis L, Bussey A, Stewart D, Ng CE: Evaluation of cisplatin response in three radiation resistant and three radiation sensitive cell lines. Anticancer Res 14: 1939-1942, 1994
21. Wyllie AH, Kerr JFR, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol 68: 251-306, 1980
22. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (Apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40: 2353-2362, 1990
23. Sorensen CM, Barry MA, Eastman A: Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82: 749-755, 1990
24. Huddart RA, Titley J, Robertson D, Williams GT, Horwich A, Cooper CS: Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. Eur J Cancer 31A: 739-746, 1995
25. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M: Topoisomerase II - reactive chemotherapy drugs induce apoptosis in thymocytes. Cancer Res 51: 1078-1085, 1991
26. Segal-Bendirdjian E, Jacquemin-Sablon A : Cisplatin resistance in a murine leukaemia cell line is associated with a defective apoptotic process. Exp Cell Res 218: 201-212, 1995
27. Eliot HE, Borner MM, Sinha BK: Differential oncogene expression and susceptibility to apoptosis in the human leukaemia HL60 cell lines: implications for etoposide resistance. Anticancer Res 15: 729-734, 1995
28. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992
29. Vogan K, Bernstein M, Leclerc JM, Brisson L, Brossard J, Brodeur GM, Pelletier J, Gros P: Absence of p53 mutations in primary neuroblastomas. Cancer Res 53: 5269-5273, 1994
30. Waber PG, Chen J, Nisen PD : Infrequency of MDM2 gene amplification in paediatric solid tumours and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 53: 6028-6030, 1993
31. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G: Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavourable histology and N-myc amplification. Am J Pathol 143: 1543-1550, 1994
32. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA, Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259, 1994
33. Wenzel A, Schwab M: The mycN/max protein complex in neuroblastoma [short review]. Eur J Cancer 31A: 516-519, 1995
34. Brodeur GM: Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer 31A: 505-510, 1995
35. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM: Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 52: 1364-1368, 1992